Patent ID: 7871631

Claim:
A method of inhibiting the lowering of antihuman TNF-α antibody activity comprising administering to a subject suffering from inflammatory bowel disease that has or is undergoing a treatment regimen involving repeated administration of anti-TNF-α antibody an effective amount of a protein source(s), carbohydrate source(s) or a combination thereof, wherein the protein source(s) comprises the amino acids at least in the following contents by dry weight of the protein source(s): L-isoleucine 2.0 to 8.0 W/W % L-leucine 4.0 to 15.0 W/W % L-lysine 4.0 to 15.0 W/W % L-methionine 2.0 to 6.0 W/W % L-phenylalanine 4.0 to 12.0 W/W % L-threonine 1.0 to 8.0 W/W % L-triptophan 0.5 to 3.0 W/W % L-valine 2.0 to 6.0 W/W % L-histidine 1.0 to 8.0 W/W % L-arginine 5.0 to 9.0 W/W % L-alanine 4.0 to 8.0 W/W % L-asparaginic acid 2.0 to 15.0 W/W % L-glutamine 0 to 15.0 W/W % Glycin 1.0 to 12.0 W/W % L-proline 2.0 to 6.0 W/W % L-serine 1.0 to 10.0 W/W % L-tyrosine 0.1 to 3.0 W/W % L-cystein 0 to 10.0 W/W % L-glutaminic acid 0 to 10.0 W/W %, and wherein the carbohydrate source(s) is at least one kind of sugar selected from the group consisting of glucose, fructose, maltose, sorbitol, xylitol and glycerin.